<DOC>
	<DOCNO>NCT00365274</DOCNO>
	<brief_summary>This phase II trial study well give SGN-30 together combination chemotherapy work treat patient newly diagnose anaplastic large cell lymphoma . Monoclonal antibody , SGN-30 , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving SGN-30 together combination chemotherapy may kill cancer cell</brief_summary>
	<brief_title>SGN-30 Combination Chemotherapy Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine efficacy monoclonal antibody SGN-30 combination cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone ( CHOP ) patient newly diagnose anaplastic large cell lymphoma ( ALCL ) . II . Determine safety combine monoclonal antibody SGN-30 CHOP chemotherapy . SECONDARY OBJECTIVES : I . Determine whether monoclonal antibody SGN-30 induce apoptosis ALCL cell vivo . II . Determine response duration patient treat regimen . III . Correlate response pretreatment serum CD30 level . IV . Determine response single-agent monoclonal antibody SGN-30 . OUTLINE : This multicenter study . Patients stratify accord anaplastic large cell kinase ( ALK ) status ( positive v negative ) . Monoclonal antibody SGN-30 monotherapy : Patients receive monoclonal antibody SGN-30 IV 2 hour weekly 3 week . Monoclonal antibody SGN-30 CHOP chemotherapy : Beginning 1 week completion monoclonal antibody SGN-30 monotherapy , patient receive monoclonal antibody SGN-30 IV 2 hour day 1 CHOP chemotherapy comprise cyclophosphamide IV 1 hour , doxorubicin hydrochloride IV 15 minute , vincristine IV 15 minute day 1 oral prednisone daily day 1-5 . Treatment repeat every 21 day 6-8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically least 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antineoplastic Agents , Alkylating</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Histologically cytologically confirm systemic anaplastic large cell lymphoma ( ALCL ) Tissue available determination anaplastic large cell kinase ( ALK ) status [ ( 2 ; 5 ) , ALKNPM translocation ] prior study entry Prior steroid topical treatment allow . Patients chronic steroid therapy may receive concomitant steroid provide stable dosage least 3 month prior enrollment Measurable disease , define &gt; = 1 lesion accurately measure &gt; = 1 dimension ( long diameter record ) &gt; = 20 mm conventional technique &gt; = 10 mm spiral CT scan The Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 OR Karnofsky PS 70100 % White Blood Count ( WBC ) &gt; = 3,000/mm³ Absolute neutrophil count &gt; = 1,500/mm³ Platelet count &gt; = 100,000/mm³ ( unless due lymphoma [ i.e. , splenomegaly and/or bone marrow involvement ] ) Bilirubin = &lt; 1.5 time upper limit normal ( ULN ) AST ALT = &lt; 2.5 time ULN Creatinine = &lt; 1.5 time ULN ( unless due lymphoma ) OR creatinine clearance &gt; =60 mL/min Left ventricular ejection fraction ( LVEF ) &gt; = 50 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No rapidly progress disease bulky disease , define mass &gt; 7 cm large diameter No primary cutaneous ALCL No known brain metastases No concurrent combination antiretroviral therapy HIVpositive patient No history allergic reaction attribute compound similar chemical biological composition monoclonal antibody SGN30 No uncontrolled intercurrent illness , include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude study compliance No prior concurrent malignancy &lt; 90 % probability survival 5 year No concurrent anticancer agent therapies No prior chemotherapy ALCL No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>murine monoclonal antibody</keyword>
	<keyword>mAb</keyword>
	<keyword>SGN-30</keyword>
	<keyword>CHOP</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin Hydrochloride</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Prednisone</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Lymphoma , Large-Cell , Anaplastic</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>Lymphoma , T-Cell</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Antineoplastic Agents , Alkylating</keyword>
	<keyword>Alkylating Agents</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Myeloablative Agonists</keyword>
	<keyword>Antibiotics</keyword>
	<keyword>Antineoplastic</keyword>
</DOC>